CP CRANBURY PHARMACEUTICALS Trademark

Trademark Overview

On Thursday, February 8, 2024, a trademark application was filed for CP CRANBURY PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the CP CRANBURY PHARMACEUTICALS trademark a serial number of 98397270. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, July 15, 2025. This trademark is owned by CRANBURY PHARMACEUTICALS. The CP CRANBURY PHARMACEUTICALS trademark is filed in the Advertising, Business and Retail Services and Pharmaceutical Products categories with the following description:

Prescription and non-prescription generic pharmaceutical medicines and preparations for the treatment of cold and allergy symptoms, respiratory disease, asthma and chronic lung disease, upper respiratory symptoms, coughs, diabetes, high cholesterol, high blood pressure, bacterial infections, malaria, hyperuricemia, gout, central nervous system disorders, namely, narcolepsy and attention deficit hyperactivity disorder, for the treatment of autism, schizophrenia, bipolar disorder, convulsions, epilepsy, nausea, vomiting, pruritus, for inducing sedation, for pain relief, and for anti-inflammation

Distributorship of prescription and non-prescription generic pharmaceutical medicines and preparations
cp cranbury pharmaceuticals

General Information

Serial Number98397270
Word MarkCP CRANBURY PHARMACEUTICALS
Filing DateThursday, February 8, 2024
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, July 15, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, July 15, 2025

Trademark Statements

Description of MarkThe mark consists of interlocked letters "CP" and word portions "CRANBURY PHARMACEUTICALS".
Goods and ServicesPrescription and non-prescription generic pharmaceutical medicines and preparations for the treatment of cold and allergy symptoms, respiratory disease, asthma and chronic lung disease, upper respiratory symptoms, coughs, diabetes, high cholesterol, high blood pressure, bacterial infections, malaria, hyperuricemia, gout, central nervous system disorders, namely, narcolepsy and attention deficit hyperactivity disorder, for the treatment of autism, schizophrenia, bipolar disorder, convulsions, epilepsy, nausea, vomiting, pruritus, for inducing sedation, for pain relief, and for anti-inflammation
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesDistributorship of prescription and non-prescription generic pharmaceutical medicines and preparations
NOT AVAILABLE"CRANBURY" and "PHARMACEUTICALS"

Classification Information

International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateThursday, February 8, 2024
Primary Code035
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, February 8, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCRANBURY PHARMACEUTICALS
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressMonmouth Junction, NJ 08852
Party NameCRANBURY PHARMACEUTICALS
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressMonmouth Junction, NJ 08852

Trademark Events

Event DateEvent Description
Thursday, February 8, 2024NEW APPLICATION ENTERED
Friday, June 7, 2024NOTICE OF DESIGN SEARCH CODE E-MAILED
Friday, June 7, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 3, 2024NON-FINAL ACTION E-MAILED
Tuesday, September 3, 2024NON-FINAL ACTION WRITTEN
Tuesday, September 3, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 3, 2024ASSIGNED TO EXAMINER
Tuesday, September 24, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 24, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 24, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, September 25, 2024NON-FINAL ACTION WRITTEN
Wednesday, September 25, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, December 23, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, December 23, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 28, 2025NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, September 25, 2024NON-FINAL ACTION E-MAILED
Monday, December 23, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, January 28, 2025FINAL REFUSAL E-MAILED
Tuesday, January 28, 2025FINAL REFUSAL WRITTEN
Monday, April 28, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 28, 2025APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Monday, April 28, 2025APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Monday, April 28, 2025TEAS REQUEST FOR RECONSIDERATION RECEIVED
Monday, April 28, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, June 10, 2025EXAMINERS AMENDMENT -WRITTEN
Tuesday, June 10, 2025NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Tuesday, June 10, 2025EXAMINERS AMENDMENT E-MAILED
Tuesday, June 10, 2025EXAMINER'S AMENDMENT ENTERED
Tuesday, June 10, 2025APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 9, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 15, 2025PUBLISHED FOR OPPOSITION
Tuesday, July 15, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Related Keywords

pharmaceuticals cranbury prescription disease disorder symptoms high respiratory pharmaceutical generic preparations medicines